http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-104203242-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D215-54 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D215-48 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D215-44 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D405-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D401-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4706 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4706 |
| filingDate | 2013-04-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2017-03-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2017-03-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-104203242-B |
| titleOfInvention | Substituted quinolines are used as bruton's tyrosine kinase inhibitor |
| abstract | The present invention relates to new quinolines, its derivative, its pharmaceutically acceptable salt, solvate and hydrate.The compound and composition of the present invention has protein kinase inhibiting activity, and can be used for the disease and condition of protein kinase mediation.Disclosed substd quinolines class includes bruton's tyrosine kinase (Btk) inhibitor. |
| priorityDate | 2012-04-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 229.